Navigation Links
TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
Date:9/25/2008

"_new">http://www.torreypinestherapeutics.com.

This press release contains forward-looking statements or predictions. Such forward-looking statements include, but are not limited to, statements regarding the plans for holding an end of Phase II meeting with the FDA, the potential for tezampanel and NGX426 as treatments for acute migraine and other indications, the potential for NGX426 to be analgesic, the anticipated timing of results for the NGX426 study in a model of capsaicin-induced pain, the anticipated timing of initiation of a Phase I multiple dose trial of NGX426, the potential for NGX267 as a treatment for xerostomia secondary to Sjogren's syndrome, the anticipated timing of results from the study of NGX267 as a treatment for xerostomia secondary to Sjogren's syndrome, the anticipated timing of the shut down of discovery operations, the ability to partner any of the company's product candidates or programs, and the ability to monetize non-core assets. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of the company's product candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of the company's product candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of the company's product candidates will support a filing for marketing approval, will be approved by the regulator
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. TorreyPines Therapeutics Reports Third Quarter 2007 Results
7. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
8. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
11. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014 -- A novel combination of microscopy and data ... Oak Ridge National Laboratory an unprecedented look at the ... and electrochemical properties. , The research team led ... surface of a perovskite manganite, a complex material that ... to understand surface behavior could benefit researchers who are ...
(Date:7/24/2014)... Security forces worldwide rely on sophisticated equipment, trained ... other public areas against terrorist attacks. A revolutionary ... about to make their job much easier. , ... Patolsky of Tel Aviv University ,s School of ... developed by the Herzliya company Tracense, picks up ...
(Date:7/24/2014)... Research and Markets has announced the addition ... report to their offering.  http://photos.prnewswire.com/prnh/20130307/600769 ... vitro growth of plant or animal cells for several ... Cell culture is a crucial step in tissue engineering ... consumables are necessary for the in vitro production of ...
(Date:7/24/2014)... 2014 Three companies from the angelMD ... Big C Competition. Out of 700 competition entrants, Chiron ... the semi-final round. In this round twenty teams are ... complete with mentoring from thought-leaders and medical entrepreneurs from ... the angelMD commitment to the Livestrong vision around the ...
Breaking Biology Technology:ORNL study reveals new characteristics of complex oxide surfaces 2Nano-sized chip 'sniffs out' explosives far better than trained dogs 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 23 angelMD Startups Make Livestrong Big C Semi-finals 2
... Consecutive Quarter of Profitability, OMAHA, Neb., Aug. 5 ... for the quarter,ended June 30, 2008. The Company reported ... second quarter 2008, compared to net income of $226,000,or ... The second quarter of 2008 represented the Company,s third ...
... ... - Net Loss Continued to Narrow - ... Updates 2008 Guidance - ... (Nasdaq: GHDX ) today reported financial results and business progress,for the quarter ended June 30, 2008., ...
... CogState Ltd. to Support Partnership, Comprehensive service ... global implementation of cognitive testing in clinical trials, ... -- United BioSource Corporation (UBC) and CogState Ltd. enter ... testing in,clinical trials., -- UBC has made a ...
Cached Biology Technology:Transgenomic Reports Second Quarter 2008 Results 2Transgenomic Reports Second Quarter 2008 Results 3Transgenomic Reports Second Quarter 2008 Results 4Transgenomic Reports Second Quarter 2008 Results 5Transgenomic Reports Second Quarter 2008 Results 6Transgenomic Reports Second Quarter 2008 Results 7Transgenomic Reports Second Quarter 2008 Results 8Transgenomic Reports Second Quarter 2008 Results 9Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress 2Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress 3Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress 4Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress 5Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress 6Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress 7Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress 8Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress 9Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress 10United BioSource Corporation and CogState Ltd. Form Strategic Partnership to Support Cognitive Assessment in Clinical Research 2United BioSource Corporation and CogState Ltd. Form Strategic Partnership to Support Cognitive Assessment in Clinical Research 3United BioSource Corporation and CogState Ltd. Form Strategic Partnership to Support Cognitive Assessment in Clinical Research 4
(Date:7/25/2014)... age girls reach puberty is influenced by ,imprinted genes,a subset ... the gene. This is the first evidence that imprinted ... details of this study were published today in the journal ... as menarche, is a marker for the timing of puberty ... menses varies between girls, is an inherited trait, and is ...
(Date:7/25/2014)... 25, 2014 Biometrics industry expands ... to digital technology for online & commerce payments while ... (NASDAQ: GOOG ), LifeLock Inc. (NYSE: ... ), Apple Inc. (NASDAQ: AAPL ) and ... NXTD) a biometric authentication company focused on the growing ...
(Date:7/24/2014)... , July 24, 2014 /PRNewswire-iReach/ -- The Geneva Healthcare ... cardiac devices, has cut emergency room wait times by ... Diego (UCSD) Medical Center, according to a recent study ... Emergency Departments are using the suite to access data ... or defibrillators. "Using Geneva,s technology platform we ...
Breaking Biology News(10 mins):Could age of first period influence development of diseases in older women? 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3
... statistics buried within patient records or detailed in newspaper ... patterns, allowing the discovery of trends that were previously ... use of interactive maps and graphs, combined with word ... events like the spread of Swine flu," said Frank ...
... This release is available in French . ... Faculty of Medicine and the CHUQ Research Center have proven ... for Duchenne muscular dystrophy. The team, led by Professor Jacques ... article published today in the online version of the scientific ...
... tested the utility of the short version of WHO-DAS II, ... with depression, "which in the case of primary care is ... In Spain, more than 10% of the population suffer ... first to screen an individual who feels depressed. For this ...
Cached Biology News:Visualization of geographic patterns may predict spread of disease 2Researchers prove the gene responsible for Duchenne muscular dystrophy can be repaired 2It takes only 5 minutes to assess disability in patients with depression 2
... This kit is designed for the fast ... vector plasmids at any position (for the ... loxP-PGK-gb2-neo-loxP cassette is designed to allow neomycin ... cells. It combines a prokaryotic promoter (gb2) ...
... instrument to offer true walk-away automation of magnetic ... cells by either positive or negative selection, RoboSep ... at one time. RoboSep is easily controlled via ... interface makes it simple and fast to set ...
Plasmid expressing the LacZ reporter gene....
Plasmid expressing Zeocin resistance gene....
Biology Products: